VENTANA PD-L1 predictive assays assess the degree and likelihood of potential patient benefit from corresponding PD-1/PD-L1 immunotherapies. The link between assay results and patient benefit has been established and verified in studies.
Using the right test to determine PD-L1 status for immunotherapy options is important. The VENTANA PD-L1 (SP142) Assay is the only approved test for TECENTRIQ. This innovative assay is the first to evaluate patient PD-L1 expression using both tumour cell and immune cell staining, providing you with information that can guide immunotherapy decisions.
The VENTANA PD-L1 (SP142) Assay:
- Clinically proven to predict UC patient response to TECENTRIQ
- Designed to enhance visual contrast of immune cell staining within the tumour microenvironment
- Stains PD-L1 in both tumour cells (TC) and tumour-infiltrating immune cells (IC)
*In the US only available on the VENTANA BenchMark ULTRA Instrument.
The PD-L1 immunologic checkpoint